Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Florbetaben (FBB ACC)

Method of Measurement (Pre-analytical Tools)
Imaging
Biomarker Measured
Amyloid
Use
Unknown
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

Compare the distribution of Florbetaben (NEURACEQ: FBB) in the brain in amyloid cerebral angiopathy (ACA) manifested by isolated hemosiderosis in non-demented patients with that observed in healthy subjects, patients with ACA and with lobar hematoma(s) and patients with Alzheimer's dementia without MRI signs in favor of ACA.

Target Population/ Population Being Studied

People with 1. ACA with isolated hemosiderosis, 2. ACA with lobar hematoma(s), or 3. Alzheimer's without ACA, and healthy volunteers

Length of Current Trial
1 day?
Number of Trial Participants

32

Estimated Trial Completion
January 2021
What is Required from Patients

injection of radioactive tracers, mild discomfort, x-ray, blood draw in clinic visit

What is Required from the Health System

PET technician, PET scanner, dyes, x-ray, phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

Centre Hospitalier Universitaire de Nīmes

“Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis (FBB ACC).” ClinicalTrials.gov. Accessed October 10, 2019.
https://clinicaltrials.gov/ct2/show/NCT02664571?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=5&rank=49